Caricamento...
Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
Abiraterone acetate, a prodrug of the CYP17A1 inhibitor abiraterone that blocks androgen biosynthesis, is approved for treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with prednisone or prednisolone 5 mg twice daily. This review evaluates the basis f...
Salvato in:
| Pubblicato in: | Oncologist |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
AlphaMed Press
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4257741/ https://ncbi.nlm.nih.gov/pubmed/25361624 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0167 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|